Latest News and Press Releases
Want to stay updated on the latest news?
-
LOS ANGELES, July 13, 2015 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a biotechnology company focused on reengineering the human microbiome to deliver novel healthcare products, announced it has preliminary...
-
LOS ANGELES, June 17, 2015 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on re-engineering the human microbiome to deliver novel healthcare products, announced that its team of...
-
LOS ANGELES, Nov. 10, 2014 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare through new pharmaceutical products, announced the appointment of Steven...
-
LOS ANGELES, Sept. 9, 2014 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that it has successfully completed the initial Phase 2...
-
LOS ANGELES, March 17, 2014 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on developing proprietary drugs with an initial focus on improving oral healthcare, announced today the close...
-
LOS ANGELES, March 7, 2014 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that the first Phase 2 Clinical Trial for its novel drug,...
-
LOS ANGELES, Aug. 22, 2013 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a Los Angeles based private biotechnology company focused on providing improved oral healthcare, announced the successful completion of a...
-
LOS ANGELES, Feb. 19, 2013 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced the successful completion of Phase 1 study enrollment for its...
-
LOS ANGELES, Oct. 4, 2012 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced the appointment of Richard Bastiani, Ph.D., as a member of its...
-
LOS ANGELES, May 24, 2012 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that its Investigational New Drug Application (IND) for...